{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:17:13Z","timestamp":1767140233050,"version":"build-2238731810"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T00:00:00Z","timestamp":1619136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T00:00:00Z","timestamp":1619136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anthracycline (A) or taxane T-based regimens are the standard early-line chemotherapy for metastatic breast cancer (BC). A previous study has shown a survival benefit of eribulin in heavily pretreated advanced\/recurrent BC patients. The present study aimed to compare the benefit of eribulin with treatment of physician\u2019s choice (TPC) as first- or second-line chemotherapy for recurrent HER2-negative BC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients with recurrent HER2-negative BC previously receiving anthracycline and taxane AT-based chemotherapy in the adjuvant or first-line setting were eligible for this open-label, randomized, parallel-group study. Patients were randomized 1:1 by the minimization method to receive either eribulin (1.4\u00a0mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      on day one and eight of each 21-day cycle) or TPC (paclitaxel, docetaxel, nab-paclitaxel or vinorelbine) until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival (PFS). Secondary endpoints included time to treatment failure (TTF), overall response rate (ORR), duration of response, and safety (UMIN000009886).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Between May 2013 and January 2017, 58 patients were randomized, 57 of whom (26 eribulin and 31 TPC) were analyzed for efficacy. The median PFS was 6.6\u00a0months with eribulin versus 4.2\u00a0months with TPC (hazard ratio: 0.72 [95% confidence interval (CI), 0.40\u20131.30],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.276). Median TTF was 6.0\u00a0months with eribulin versus 3.6\u00a0months with TPC (hazard ratio: 0.66 [95% CI, 0.39\u20131.14],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.136). Other endpoints were also similar between groups. The most common grade\u2009\u2265\u20093 adverse event was neutropenia (22.2% with eribulin versus 16.1% with TPC).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Eribulin seemed to improve PFS or TTF compared with TPC without statistical significance. Further validation studies are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10147-021-01920-0","type":"journal-article","created":{"date-parts":[[2021,4,24]],"date-time":"2021-04-24T16:20:19Z","timestamp":1619281219000},"page":"1229-1236","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19)"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6512-7051","authenticated-orcid":false,"given":"Kenjiro","family":"Aogi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Kitada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Sangai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoichiro","family":"Ohtani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Aruga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetoshi","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeto","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuaki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Takao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norikazu","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Toi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,23]]},"reference":[{"key":"1920_CR1","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.breast.2012.03.003","volume":"21","author":"F Cardoso","year":"2012","unstructured":"Cardoso F, Costa A, Norton L et al (2012) 1st international consensus guidelines for advanced breast cancer (ABC 1). Breast 21:242\u2013252","journal-title":"Breast"},{"key":"1920_CR2","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10549-014-3144-y","volume":"148","author":"C Twelves","year":"2014","unstructured":"Twelves C, Cortes J, Vahdat L et al (2014) Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res Treat 148:553\u2013561","journal-title":"Breast Cancer Res Treat"},{"key":"1920_CR3","doi-asserted-by":"publisher","first-page":"5760","DOI":"10.1158\/0008-5472.CAN-04-1169","volume":"64","author":"G Kuznetsov","year":"2004","unstructured":"Kuznetsov G, Towle MJ, Cheng H et al (2004) Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res 64:5760\u20135766","journal-title":"Cancer Res"},{"key":"1920_CR4","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1158\/1535-7163.MCT-04-0345","volume":"4","author":"MA Jordan","year":"2005","unstructured":"Jordan MA, Kamath K, Manna T et al (2005) The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 4:1086\u20131095","journal-title":"Mol Cancer Ther"},{"key":"1920_CR5","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1158\/1535-7163.MCT-08-0095","volume":"7","author":"T Okouneva","year":"2008","unstructured":"Okouneva T, Azarenko O, Wilson L et al (2008) Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther 7:2003\u20132011","journal-title":"Mol Cancer Ther"},{"key":"1920_CR6","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1021\/bi901810u","volume":"49","author":"JA Smith","year":"2010","unstructured":"Smith JA, Wilson L, Azarenko O et al (2010) Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry 49:1331\u20131337","journal-title":"Biochemistry"},{"key":"1920_CR7","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","volume":"377","author":"J Cortes","year":"2011","unstructured":"Cortes J, O\u2019Shaughnessy J, Loesch D et al (2011) Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377:914\u2013923","journal-title":"Lancet"},{"key":"1920_CR8","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1093\/annonc\/mdr444","volume":"23","author":"K Aogi","year":"2012","unstructured":"Aogi K, Iwata H, Masuda N et al (2012) A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer. Ann Oncol 23:1441\u20131448","journal-title":"Ann Oncol"},{"key":"1920_CR9","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1634\/theoncologist.12-7-785","volume":"12","author":"S Verma","year":"2007","unstructured":"Verma S, Mark CM (2007) First-line treatment options for patients with her-2-negative metastatic breast cancer: the impact of modern adjuvant chemotherapy. Oncologist 12:785\u2013797","journal-title":"Oncologist"},{"key":"1920_CR10","doi-asserted-by":"publisher","first-page":"7199","DOI":"10.1200\/JCO.2005.01.149","volume":"23","author":"LV Rubinstein","year":"2005","unstructured":"Rubinstein LV, Korn EL, Freidlin B et al (2005) Design issues of randomized phase ii trials and a proposal for phase ii screening trials. J Clin Oncol 23:7199\u20137206","journal-title":"J Clin Oncol"},{"key":"1920_CR11","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1200\/JCO.1998.16.10.3439","volume":"16","author":"R Fossati","year":"1998","unstructured":"Fossati R, Confalonieri C, Torri V et al (1998) Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 16:3439\u20133460","journal-title":"J Clin Oncol"},{"key":"1920_CR12","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/BF01806751","volume":"1","author":"AH Paterson","year":"1981","unstructured":"Paterson AH, Szafran O, Cornish F et al (1981) Effect of chemotherapy on survival in metastatic breast cancer. Breast Cancer Res Treat 1:357\u2013363","journal-title":"Breast Cancer Res Treat"},{"key":"1920_CR13","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/bjc.1993.146","volume":"67","author":"RP A\u2019Hern","year":"1993","unstructured":"A\u2019Hern RP, Smith IE, Ebbs SR (1993) Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. Br J Cancer 67:801\u2013805","journal-title":"Br J Cancer"},{"key":"1920_CR14","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s10549-014-2923-9","volume":"146","author":"K McIntyre","year":"2014","unstructured":"McIntyre K, O\u2019Shaughnessy J, Schwartzberg L et al (2014) Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer. Breast Cancer Res Treat 146:321\u2013328","journal-title":"Breast Cancer Res Treat"},{"key":"1920_CR15","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1111\/tbj.13686","volume":"26","author":"J Cortes","year":"2020","unstructured":"Cortes J, Twelves C (2020) Impact of the number of prior chemotherapy regimens on outcomes for patients with metastatic breast cancer treated with eribulin: a post hoc pooled analysis. Breast J 26:1347\u20131351","journal-title":"Breast J"},{"key":"1920_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-019-00890-5","author":"K Inoue","year":"2020","unstructured":"Inoue K, Takahashi M, Mukai H et al (2020) Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting. Invest New Drugs. https:\/\/doi.org\/10.1007\/s10637-019-00890-5","journal-title":"Invest New Drugs"},{"key":"1920_CR17","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1002\/ijc.32402","volume":"145","author":"W Jacot","year":"2019","unstructured":"Jacot W, Heudel PE, Fraisse J et al (2019) Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program. Int J Cancer 145:3359\u20133369","journal-title":"Int J Cancer"},{"key":"1920_CR18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.4103\/ijc.IJC_458_18","volume":"57","author":"M Sari","year":"2020","unstructured":"Sari M, Saip P (2020) Eribulin monotherapy in heavily pretreated metastatic breast cancer patients in real life. Indian J Cancer 57:55\u201361","journal-title":"Indian J Cancer"},{"key":"1920_CR19","unstructured":"Eribulin mesylate or paclitaxel as first or second-line therapy in treating patients with recurrent stage iiic-iv breast cancer."},{"key":"1920_CR20","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1200\/JCO.2008.18.5397","volume":"27","author":"WJ Gradishar","year":"2009","unstructured":"Gradishar WJ, Krasnojon D, Cheporov S et al (2009) Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 27:3611\u20133619","journal-title":"J Clin Oncol"},{"key":"1920_CR21","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40360-019-0367-x","volume":"20","author":"MB Sirv\u00e9n","year":"2019","unstructured":"Sirv\u00e9n MB, Fern\u00e1ndez-Ortega A, Stradella A et al (2019) Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center. BMC Pharmacol Toxicol 20:68","journal-title":"BMC Pharmacol Toxicol"}],"updated-by":[{"DOI":"10.1007\/s10147-022-02237-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:00:00Z","timestamp":1664236800000}},{"DOI":"10.1007\/s10147-021-01940-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T00:00:00Z","timestamp":1622073600000}}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-021-01920-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-021-01920-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-021-01920-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T03:07:35Z","timestamp":1664334455000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-021-01920-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,23]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1920"],"URL":"https:\/\/doi.org\/10.1007\/s10147-021-01920-0","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,23]]},"assertion":[{"value":"20 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10147-021-01940-w","URL":"https:\/\/doi.org\/10.1007\/s10147-021-01940-w","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2022","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10147-022-02237-2","URL":"https:\/\/doi.org\/10.1007\/s10147-022-02237-2","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kenjiro Aogi received honoraria from Chugai, Eisai, AstraZeneca, Taiho, Novartis, Daiichi Sankyo, Mochida, Ono and Eli Lilly, research funding from Chugai, Eisai, Takeda and Sanofi; Takashi Sangai has received research funding from Eisai; Shoichiro Ohtani received honoraria from Chugai, Eli Lilly, AstraZeneca, Pfizer and Eisai; Tomoyuki Aruga received honoraria from Eisai; Hidetoshi Kawaguchi received honoraria from Pfizer, Chugai, AstraZeneca, Eli Lilly, Kyowa-Kirin, Novartis, Taiho and Takeda; Nobuaki Sato has received remuneration from Chugai, Taiho and Kyowa-Kirin; Satoshi Morita received honoraria from AstraZeneca, Bristol-Myers Squibb Company, Chugai, Eisai, Eli Lilly, MSD, Pfizer and Taiho; Norikazu Masuda received honoraria from Chugai, AstraZeneca, Pfizer, Eli Lilly, Eisai, Takeda, research funding from Chugai, AstraZeneca, Kyowa-Kirin, MSD, Novartis, Pfizer, Eli Lilly, Eisai, Nippon Kayaku, Daiichi Sankyo; Masakazu Toi received honoraria from Eisai, Taiho, Takeda, Kyowa-Kirin, Chugai, Daiichi Sankyo, AstraZeneca, Pfizer and Eli Lilly, research funding from Eisai, Taiho, Takeda, Kyowa-Kirin, Chugai, Daiichi Sankyo, AstraZeneca and Pfizer, others for Board of directors of JBCRG association, Kyoto Breast Cancer Research Network; Shinji Ohno has received honoraria from AstraZeneca, Eisai, Pfizer, Chugai and Eli Lilly, research funding from Eisai and Taiho; Kenichi Watanabe, Masahiro Kitada, Tomomi Fujisawa, Shigeto Maeda, Shintaro Takao and Takashi Morimoto has no conflict of interest. Conflict of interest refers to any relationship that may influence the study results and includes financial and personal factors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest and sources of funding"}}]}}